Mallia Therapeutics

What Mallia Therapeutics does

Mallia Therapeutics GmbH is a privately held German biopharmaceutical company, headquartered in Erlangen and founded in 2023, that develops recombinant-protein therapeutics based on the soluble CD83 (sCD83) protein — a key mediator of inflammation resolution and tissue regeneration identified through more than 20 years of immunological research. Its active therapeutic candidate, MAL-856, is a recombinant protein structurally related to sCD83 and is being positioned for clinical development in three indication areas: hair loss/alopecia, wound healing (chronic wounds), and inflammatory/autoimmune skin disorders. The company is structured as the therapeutic division of the broader Mallia group, operating alongside sister entity Mallia Aesthetics GmbH, which markets consumer cosmetic products using MAL-838 — a sister ingredient also derived from the sCD83 platform.

The Mallia Aesthetics division sells direct-to-consumer through the 8t3.com e-commerce storefront, offering hormone-free topical serums including the 8T3 Essentials Hair Serum and the Lash & Brow Serum. A combined consumer cohort of 23 participants across two six-month studies reported an 87% improvement-or-stabilization rate, an average 30% increase in hair density (with super-responders reaching 193%), 100% reported good tolerability, and 81% of lash/brow users reported longer eyelashes with up to 39% lash-length gain. These outcomes are being used by the company both to validate the underlying mechanistic premise and to build a consumer cash-flow and brand asset ahead of regulated clinical work.

On the therapeutic side, Mallia Therapeutics is pre-clinical with no disclosed commercial license or royalty revenue; the stated near-term plan is to enter clinical trials within two years of the July 2023 seed funding round, targeting first alopecia and adjacent inflammatory indications. Headcount is reported in the 1-10 range and the company is actively building a network of academic, industrial, and regulatory collaborators to translate the platform into IND-ready assets. No management team profiles, patent records, formal partnerships, or institutional investors were disclosed in the source data, and the seed round amount itself is not publicly quantified.

Name

Mallia Therapeutics

Legal name

Mallia Therapeutics GmbH

Website

https://mallia-therapeutics.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Mallia Therapeutics is a German biopharmaceutical company developing sCD83-based recombinant-protein therapies (MAL-856) for hair loss, wound healing, and inflammatory/autoimmune diseases, with a consumer sister division selling hormone-free hair and lash serums via DTC e-commerce.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Cosmetics, Beauty Supplies, and Perfume Retailers (456120), Health and Personal Care Retailers (4561)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industries

Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Treatment Skincare (Serums, Actives, Acne & Anti-aging) (CRABAAAB), Sensitive Skin & Barrier Repair (CRABAAAG)

Keywords

• Biopharmaceutical therapeutics
• Hair loss treatment
• Immune modulation drugs
• Recombinant protein therapy
• Clinical stage biopharma

Headquarters

HQ city

Erlangen

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Consumer skincare products (Mallia Aesthetics): Direct-to-consumer sales of hormone-free cosmetic serums including 8T3 Essentials Hair Serum and Lash & Brow Serum. Products contain proprietary MAL-838 ingredient derived from sCD83 protein.
2. Therapeutic treatments (clinical stage): Pre-clinical and clinical-stage therapeutic treatments based on MAL-856 molecule targeting alopecia, wound healing, and inflammatory/autoimmune diseases. Revenue model not yet established as treatments are still in development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Mallia Therapeutics is the therapeutic division of Mallia, developing MAL-856 — a recombinant protein structurally related to soluble CD83 (sCD83) — for treating alopecia, chronic wound healing, and inflammatory/autoimmune skin diseases. Its sister division, Mallia Aesthetics, commercializes MAL-838, a proprietary sCD83-derived cosmetic ingredient, in hormone-free topical serums (8T3 Essentials Hair Serum and Lash & Brow Serum) sold direct-to-consumer.

Product overview

Mallia Therapeutics operates as the therapeutic division of Mallia, focused on translating immunological research into clinical therapies. The company develops treatments based on MAL-856, a recombinant protein structurally related to sCD83, targeting hair loss/alopecia, wound healing, and inflammatory/autoimmune diseases. A separate consumer division, Mallia Aesthetics, commercializes products containing MAL-838 (based on the same sCD83 protein platform) in the form of topical serums for hair, lash, and brow enhancement.

Differentiator

Problem solved

Functional benefit

Brands

• MAL-856: A recombinant protein structurally related to soluble sCD83, at the heart of Mallia Therapeutics' therapeutic research. Used for developing treatments for hair loss, wound healing, and inflammatory/autoimmune diseases.
• MAL-838

Products and services

• MAL-856 A recombinant protein structurally related to soluble sCD83, the active ingredient in Mallia's therapeutic pipeline. Being developed as a treatment for hair loss/alopecia, wound healing, and inflammatory/autoimmune diseases through immune modulation and tissue regeneration.
• 8T3 Essentials Hair Serum A hormone-free topical hair growth serum containing MAL-838 (sCD83-derived) for consumers seeking non-hormonal hair loss solutions. Reported 87% participant response rate, 30% average increase in hair density, and up to 193% gains in super-responders over a 6-month consumer study.
• 8T3 Essentials Lash & Brow Serum A hormone-free serum for eyelash and eyebrow enhancement using MAL-838. In a 12-week consumer study, 81% of participants reported longer eyelashes, with objective measurements showing up to 39% increase in lash length and 32% in lash intensity.

Quantifiable outcome

• 87% of participants showed improvement or stabilization of hair status in 6-month study
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• RevitaLash Cosmetics: Consumer beauty brand focused on lash, brow, and hair-enhancing cosmetic products sold DTC and through salons. Comparable as the consumer-side equivalent to Mallia Aesthetics' 8T3 Lash & Brow Serum business.
• Stemson Therapeutics: Pre-clinical biotech developing iPSC-derived cell therapy for hair regeneration. Comparable as a venture-stage regenerative medicine company targeting the alopecia market with a novel approach.
• Grande Cosmetics: Consumer beauty brand selling lash and brow enhancing serums, including growth serums targeting the same consumer use case as Mallia's 8T3 Lash & Brow Serum. Directly competes in the lash/brow enhancement market.
• Follica: Biotech developing a regenerative approach to hair loss through follicle neogenesis. Directly comparable as a hair-loss-focused biotech pursuing novel mechanisms beyond minoxidil/finasteride.
• Aclaris Therapeutics: Clinical-stage specialty dermatology pharmaceutical company developing novel treatments for hair loss (alopecia areata) and inflammatory skin diseases. Closely comparable to Mallia's therapeutic focus on dermatology and hair loss indications.
• Pelage Pharmaceuticals: Clinical-stage biotech developing novel topical treatments for hair loss, with a focus on mechanisms that promote hair growth. Highly comparable as a hair-loss therapeutic developer at similar stage.

Emerging players

• K18 Biomimetic Hairscience: Biotech-inspired consumer hair brand leveraging proprietary peptide technology for hair repair. Comparable to Mallia Aesthetics as an emerging science-led consumer hair care brand positioned as a more effective alternative to traditional products.

Broad incumbents

• Pfizer: Global pharma giant that has historically commercialized minoxidil-based hair loss treatments. A broad incumbent whose dermatology/Aesthetics portfolio and commercial reach dwarf Mallia's current capabilities.
• L'Oréal: Global beauty conglomerate with extensive hair care, scalp, and dermatological skincare lines (including Vichy, La Roche-Posay). Comparable to Mallia Aesthetics' consumer skincare/hair positioning and an active acquirer in dermatological beauty.
• Johnson & Johnson: Owns Rogaine (minoxidil), the leading OTC hair loss brand. A broad incumbent with significant dermatology and consumer health exposure, representing both a competitor and potential acquirer of dermatology-focused biotech assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mallia Therapeutics